WAM
ITCI

Wealthspire Advisors (Maryland)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-27
Closed – – 1857
2016
Q3 		$0 Buy
+27
New +$1.09K ﹤0.01% 1813

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s ITCI Position: Q4 2016 in Review

Wealthspire Advisors (Maryland) sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2016, closing a stake of 27 shares.

Wealthspire Advisors (Maryland) first reported a position in ITCI in Q3 2016 and held it in 1 quarter. The position peaked at $0 in Q3 2016. 129 funds tracked by Wall St. Rank hold ITCI as of Q4 2016.

  • Wealthspire Advisors (Maryland) reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2016 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 27 Intra-Cellular Therapies Inc. shares in Q4 2016.
  • Wealthspire Advisors (Maryland) first reported a position in Intra-Cellular Therapies Inc. in Q3 2016 and held it in 1 quarter.
  • Wealthspire Advisors (Maryland)'s Intra-Cellular Therapies Inc. position peaked at $0 in Q3 2016.
  • 129 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2016.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q4 2016, filed 6 Feb 2017.